Latest & greatest articles for gabapentin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on gabapentin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on gabapentin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for gabapentin

1. Gabapentin for Alcohol Use Disorder: Decrease pints with a pill?

Gabapentin for Alcohol Use Disorder: Decrease pints with a pill? November 30, 2020 Gabapentin for Alcohol Use Disorder: Decrease pints with a pill? Clinical Question: Is gabapentin effective in treating alcohol use disorder (AUD)? Bottom Line: More patients on gabapentin (27%) could avoid heavy drinking days (example >5 standard drinks/day) compared to those on placebo (9%). There is mixed evidence for gabapentin and abstinence. Gabapentin may be considered as a second-line option (off-label (...) ) for AUD (after acamprosate or naltrexone). Concerns regarding abuse/misuse and drug related harms should inform therapeutic discussion. Evidence: • Results statistically significant unless noted. o Systematic review, 7 randomized controlled trials (RCTs), 3-26 weeks, 730 participants, with alcohol dependence or AUD, 300-3600mg gabapentin/day (immediate or delayed release) versus placebo, most included regular follow-up visits after ~3 days abstinence. Gabapentin: 1 ? Decreased percentage of heavy

2021 Tools for Practice

2. Gabapentin as an adjunct to paracervical block for perioperative pain management for first-trimester uterine aspiration: a randomized controlled trial

Gabapentin as an adjunct to paracervical block for perioperative pain management for first-trimester uterine aspiration: a randomized controlled trial Gabapentin as an adjunct to paracervical block for perioperative pain management for first-trimester uterine aspiration: a randomized controlled trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) Am J Obstet Gynecol Actions . 2020 Dec;223(6):884.e1-884.e10. doi: 10.1016/j.ajog.2020.06.011. Epub 2020 Jun 11. Gabapentin as an adjunct to paracervical block for perioperative pain management for first-trimester uterine aspiration: a randomized controlled trial , , , , , , Affiliations Expand Affiliations 1 Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA. Electronic address: tiffany.p.hailstorks@emory.edu. 2 Department of Gynecology and Obstetrics

2021 EvidenceUpdates

3. Gabapentin to reduce pain in women aged between 18 and 50 years with chronic pelvic pain: the GaPP2 RCT Full Text available with Trip Pro

Gabapentin to reduce pain in women aged between 18 and 50 years with chronic pelvic pain: the GaPP2 RCT Gabapentin to reduce pain in women aged between 18 and 50 years with chronic pelvic pain: the GaPP2 RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need (...) . >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Gabapentin did not reduce pain scores or improve other outcomes in women with chronic pelvic pain, and was associated with an increase in serious adverse effects. {{author}} {{($index , , , , , , , , & . Catherine A Hewitt 1 , Katy Vincent 2 , Lee J Middleton 1 , Liana Romaniuk 3 , Magda Koscielniak 4 , Ann M Doust 4 , Judy Birch 5 , Heather Whalley 3 , Jane P Daniels 6, 7 , Andrew W Horne 4, * 1 Birmingham

2020 NIHR HTA programme

4. Gabapentin for chronic pelvic pain in women (GaPP2): a multicentre, randomised, double-blind, placebo-controlled trial. Full Text available with Trip Pro

Gabapentin for chronic pelvic pain in women (GaPP2): a multicentre, randomised, double-blind, placebo-controlled trial. Chronic pelvic pain affects 2-24% of women worldwide and evidence for medical treatments is scarce. Gabapentin is effective in treating some chronic pain conditions. We aimed to measure the efficacy and safety of gabapentin in women with chronic pelvic pain and no obvious pelvic pathology.We performed a multicentre, randomised, double-blind, placebo-controlled randomised trial (...) in 39 UK hospital centres. Eligible participants were women with chronic pelvic pain (with or without dysmenorrhoea or dyspareunia) of at least 3 months duration. Inclusion criteria were 18-50 years of age, use or willingness to use contraception to avoid pregnancy, and no obvious pelvic pathology at laparoscopy, which must have taken place at least 2 weeks before consent but less than 36 months previously. Participants were randomly assigned in a 1:1 ratio to receive gabapentin (titrated

2020 Lancet

5. Gabapentin reduced drinking in patients with alcohol use disorder and alcohol withdrawal symptoms. (Abstract)

Gabapentin reduced drinking in patients with alcohol use disorder and alcohol withdrawal symptoms. Anton RF, Latham P, Voronin K, et al. Efficacy of gabapentin for the treatment of alcohol use disorder in patients with alcohol withdrawal symptoms: a randomized clinical trial. JAMA Intern Med. 2020;180:1-9. 32150232.

2020 Annals of Internal Medicine

6. Gabapentin for phantom limb pain after amputation in pediatric oncology: a systematic review protocol Full Text available with Trip Pro

Gabapentin for phantom limb pain after amputation in pediatric oncology: a systematic review protocol Inplasy Protocol 440 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols

7. The analgesic evaluation of gabapentin for arthroscopy: a meta-analysis of randomized controlled trials Full Text available with Trip Pro

The analgesic evaluation of gabapentin for arthroscopy: a meta-analysis of randomized controlled trials The analgesic evaluation of gabapentin for arthroscopy: a meta-analysis of randomized controlled trials | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should (...) not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article The analgesic evaluation of gabapentin for arthroscopy: a meta-analysis of randomized controlled trials Feiri Huang, Hifan Yang, Zhongliang Su, Xiaosheng Gao Feiri Huang wenzhou people hospital Hifan Yang wenzhou people hospital Zhongliang Su wenzhou people hospital Xiaosheng Gao Wenzhou Medical College Affiliated Yueqing Hospital Corresponding Author

2020 Research Square

8. Pregabalin (Lyrica or other brands) and gabapentin (Neurontin or other brands): known dangers and uncertainties during pregnancy

Pregabalin (Lyrica or other brands) and gabapentin (Neurontin or other brands): known dangers and uncertainties during pregnancy Prescrire IN ENGLISH - Spotlight ''Pregabalin (Lyrica° or other brands) and gabapentin (Neurontin° or other brands): known dangers and uncertainties during pregnancy'', 1 May 2020 {1} {1} {1} | | > > > Pregabalin (Lyrica° or other brands) and gabapentin (Neurontin° or other brands): known dangers and uncertainties during pregnancy Spotlight Every month, the subjects (...) in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Pregabalin (Lyrica° or other brands) and gabapentin (Neurontin° or other brands): known dangers and uncertainties during pregnancy Taken during pregnancy, pregabalin and gabapentin expose the newborn to harmful effects. Pregabalin and gabapentin are two very similar drugs which are widely used in France, particularly as antiepileptics and to treat

2020 Prescrire

9. Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial

Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other (...) for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation JAMA Intern Med Actions . 2020 Mar 9;e200249. doi: 10.1001/jamainternmed.2020.0249. Online ahead of print. Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial , , , , , , Affiliations Expand Affiliation 1 Addiction Sciences Division, Department of Psychiatry and Behavioral Sciences, Medical University of South

2020 EvidenceUpdates

10. Aetiology of Neuropathic Pain (NP) Along with Role of Gabapentinoids Like Pregabalin and Gabapentin in Treating the Excruciating Pain Besides Other Newer Alternatives-a Systematic Review Full Text available with Trip Pro

Aetiology of Neuropathic Pain (NP) Along with Role of Gabapentinoids Like Pregabalin and Gabapentin in Treating the Excruciating Pain Besides Other Newer Alternatives-a Systematic Review Journal of Anesthesia & Pain Medicine Volume 5 | Issue 1 | 21 Aetiology of Neuropathic Pain (NP) Along with Role of Gabapentinoids Like Pregabalin and Gabapentin in Treating the Excruciating Pain Besides Other Newer Alternatives-a Systematic Review Review Article Kulvinder Kochar Kaur 1 *, Gautam Allahbadia 2 (...) other modes of therapy. Methods We used the search engine Pubmed, utilizing MeSH terms, Neuropathic pain (NP); gabapentinoids; Pregabalin; gabapentin; mode of action; post amputation pain; opioids; fentanyl; corticosteroid; post herpetic neuralgia. Results and Discussion We found a total of 8661 articles out of which we selected 73 articles for this review. No meta-analysis was done. Role of Gabapentinoids in Neuropathic pain (NP) 1ST line therapy regarding managing NP are gabapentinoids, tricyclic

2020 Journal of Anesthesia & Pain Medicine

11. Perioperative Gabapentin in Pediatric Thoracic Surgery Patients-Randomized, Placebo-Controlled, Phase 4 Trial (Abstract)

Perioperative Gabapentin in Pediatric Thoracic Surgery Patients-Randomized, Placebo-Controlled, Phase 4 Trial To determine whether the use of perioperative gabapentin reduces postoperative pain and anxiety, decreases ropivacaine consumption and side effects, and improves patient satisfaction.Randomized, placebo-controlled, phase 4 trial.Participants, care providers, investigators, data analysts.Department of Thoracic Surgery of the Institute of Tuberculosis and Lung Disease, Rabka Zdrój Branch (...) , Poland.Forty patients undergoing the Ravitch procedure.Patients aged nine to 17 years were randomized into a gabapentin (preoperative 15 mg/kg, treatment) or placebo group. Postoperative analgesia included gabapentin (7.5 mg/kg) or placebo two times per day for three days, epidural ropivacaine + fentanyl, paracetamol, nonsteroidal anti-inflammatory drugs, and metamizol as a "rescue drug." Pain, anxiety, analgesic consumption, side effects, and patient satisfaction were recorded.There was no statistically

2019 EvidenceUpdates

12. Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April

Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April As of 1 April 2019, pregabalin and gabapentin are controlled under the Misuse (...) of Drugs Act 1971 as Class C substances and scheduled under the Misuse of Drugs Regulations 2001 as Schedule 3. Evaluate patients carefully for a history of drug abuse before prescribing pregabalin and gabapentin and observe patients for development of signs of abuse and dependence. Published 16 April 2019 From: Therapeutic area: , , , Contents Advice for healthcare professionals: to reflect growing concern about abuse, both pregabalin and gabapentin are now classified as Class C controlled substances

2019 MHRA Drug Safety Update

13. Gabapentin and pregabalin: Are high doses justified?

Gabapentin and pregabalin: Are high doses justified? Gabapentin and pregabalin: Are high doses justified? January 2019 Mailing Address: Therapeutics Initiative The University of British Columbia Department of Anesthesiology, Pharmacology & Therapeutics 2176 Health Sciences Mall Vancouver, BC Canada V6T 1Z3 Tel.: 604 822 0700 Fax: 604 822 0701 E-mail: info@ti.ubc.ca www.ti.ubc.ca 117 A nalgesia once seemed a relatively straightfor- ward aspect of medicine. Recommendations in textbooks (...) and guidelines were definitive, albeit heavily conflicted. Even recent guidelines encourage dose titration, based on an implicit, if unsupported, notion that more is likely to be better. 1 Recent experiments and systematic reviews show that drugs seldom outperform placebo significantly in chronic pain. Even old standards like acetaminophen and amitriptyline do not stand up well to careful scru- tiny of randomized placebo-controlled trials. 2,3 Recent evidence confirms that gabapentin and pregabalin

2019 Therapeutics Letter

14. Gabapentin

Gabapentin Top results for gabapentin - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for gabapentin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

15. Gabapentin for Chronic Neuropathic Pain. (Abstract)

Gabapentin for Chronic Neuropathic Pain. Is gabapentin associated with pain relief in people with chronic neuropathic pain?Oral gabapentin (1200-3600 mg/d for 4-12 weeks) for patients with moderate or severe neuropathic pain from postherpetic neuralgia (PHN) or painful diabetic neuropathy (PDN) is associated with pain reduction of at least 50% in 14% to 17% more patients than placebo.

2018 JAMA

16. Effect of Perioperative Gabapentin on Postoperative Pain Resolution and Opioid Cessation in a Mixed Surgical Cohort: A Randomized Clinical Trial Full Text available with Trip Pro

Effect of Perioperative Gabapentin on Postoperative Pain Resolution and Opioid Cessation in a Mixed Surgical Cohort: A Randomized Clinical Trial Guidelines recommend using gabapentin to decrease postoperative pain and opioid use, but significant variation exists in clinical practice.To determine the effect of perioperative gabapentin on remote postoperative time to pain resolution and opioid cessation.A randomized, double-blind, placebo-controlled trial of perioperative gabapentin was conducted (...) of participants with continued pain or opioid use at 6 months and 1 year.Of 1805 patients screened for enrollment, 1383 were excluded, including 926 who did not meet inclusion criteria and 273 who declined to participate. Overall, 8% of patients randomized were lost to follow-up. A total of 202 patients were randomized to active placebo and 208 patients were randomized to gabapentin in the intention-to-treat analysis (mean [SD] age, 56.7 [11.7] years; 256 (62.4%) women and 154 (37.6%) men). Baseline

2018 EvidenceUpdates

17. Gabapentin for Adults with Neuropathic Pain: A Review of the Clinical Effectiveness

Gabapentin for Adults with Neuropathic Pain: A Review of the Clinical Effectiveness Gabapentin for Adults with Neuropathic Pain: A Review of the Clinical Effectiveness | CADTH.ca Find the information you need Gabapentin for Adults with Neuropathic Pain: A Review of the Clinical Effectiveness Gabapentin for Adults with Neuropathic Pain: A Review of the Clinical Effectiveness Last updated: March 12, 2018 Project Number: RC0970-000 Product Line: Research Type: Drug Report Type: Summary (...) with Critical Appraisal Result type: Report Question What is the clinical effectiveness of gabapentin for adults with neuropathic pain? Key Message The findings from four systematic reviews and one RCT for gabapentin (GBP) compared to placebo or active comparators is limited by quantity and quality of evidence for studies on neuropathic pain associated with conditions including chronic lower back pain, fibromyalgia, mixed neuropathic pain, and nerve injury pain. While some studies reported little

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

18. Multiple sclerosis: Gabapentin

Multiple sclerosis: Gabapentin Gabapentin | Prescribing information | Multiple sclerosis | CKS | NICE Search CKS… Menu Gabapentin Multiple sclerosis: Gabapentin Last revised in October 2019 Gabapentin The use of gabapentin for spasticity and for oscillopsia in people with multiple sclerosis is off-label. For detailed prescribing information, see the section on in the CKS topic on . © .

2018 NICE Clinical Knowledge Summaries

19. Palliative cancer care - pain: What issues should I consider before prescribing gabapentin?

Palliative cancer care - pain: What issues should I consider before prescribing gabapentin? Gabapentin | Prescribing information | Palliative cancer care - pain | CKS | NICE Search CKS… Menu Gabapentin Palliative cancer care - pain: What issues should I consider before prescribing gabapentin? Last revised in October 2016 What issues should I consider before prescribing gabapentin? For prescribing information, see the section on in the CKS topic on . © .

2018 NICE Clinical Knowledge Summaries

20. Comparative Efficacy and Safety of Gabapentin, Pregabalin, Oxcarbazepine and Duloxetine in Diabetic Peripheral Neuropathy - A Network Meta-Analysis Full Text available with Trip Pro

Comparative Efficacy and Safety of Gabapentin, Pregabalin, Oxcarbazepine and Duloxetine in Diabetic Peripheral Neuropathy - A Network Meta-Analysis Comparative Efficacy and Safety of Gabapentin, Pregabalin, Oxcarbazepine and Duloxetine in Diabetic Peripheral Neuropathy - A Network Meta-Analysis Toggle navigation Proceedings for Annual Meeting of The Japanese Pharmacological Society Online ISSN : 2435-4953 / / / Article overview WCP2018 (The 18th World Congress of Basic and Clinical Pharmacology (...) ) Session ID : WCP2018_PO2-7-13 DOI Conference information Host: The Japanese Pharmacological Society, The Japanese Society of Clinical Pharmacology Name : WCP2018 (18th World Congress of Basic and Clinical Pharmacology) Location : Kyoto Date : July 01, 2018 - July 06, 2018 Poster session Comparative Efficacy and Safety of Gabapentin, Pregabalin, Oxcarbazepine and Duloxetine in Diabetic Peripheral Neuropathy - A Network Meta-Analysis , , Author information Karan B Shah Department Of Pharmacology, Smt

2018 Proceedings for Annual Meeting of The Japanese Pharmacological Society